ChemicalBook >> CAS DataBase List >>UMiroliMus

UMiroliMus

CAS No.
851536-75-9
Chemical Name:
UMiroliMus
Synonyms
TRM986;TRM 986;TRM-986;BioliMus;UMiroliMus;BIOLIMUS A9;BioliMus A9 UMiroliMus;BioliMus, BioliMus A9, TRM 986;Rapamycin, 42-O-(2-ethoxyethyl)-
CBNumber:
CB22470849
Molecular Formula:
C55H87NO14
Molecular Weight:
986.28
MDL Number:
MFCD22124433
MOL File:
851536-75-9.mol
Last updated:2023-05-21 10:59:17

UMiroliMus Properties

Boiling point 991.0±75.0 °C(Predicted)
Density 1.15±0.1 g/cm3(Predicted)
storage temp. Store at -20°C
solubility DMF: Soluble; DMSO: Soluble; Ethanol: Soluble; Methanol: Soluble
form A solid
pka 10.40±0.70(Predicted)
FDA UNII U36PGF65JH

UMiroliMus price More Price(6)

Manufacturer Product number Product description CAS number Packaging Price Updated Buy
Cayman Chemical 23585 Umirolimus ≥95% 851536-75-9 1mg $117 2024-03-01 Buy
Cayman Chemical 23585 Umirolimus ≥95% 851536-75-9 5mg $463 2024-03-01 Buy
TRC U710005 Umirolimus 851536-75-9 5mg $370 2021-12-16 Buy
TRC U710005 Umirolimus 851536-75-9 1mg $85 2021-12-16 Buy
American Custom Chemicals Corporation API0007715 UMIROLIMUS 95.00% 851536-75-9 5MG $504 2021-12-16 Buy
Product number Packaging Price Buy
23585 1mg $117 Buy
23585 5mg $463 Buy
U710005 5mg $370 Buy
U710005 1mg $85 Buy
API0007715 5MG $504 Buy

UMiroliMus Chemical Properties,Uses,Production

Description

Coronary stents have dramatically improved the success rate of interventional cardiology in recent years, and stent implantation has become the standard of care in percutaneous coronary interventions. However, the long-term success of coronary stenting is hampered by a high rate of restenosis (i.e., recurrence of stenosis, or reblocking), which is caused by proliferation and migration of smooth muscle cells and production of extracellular matrix. The Biomatrix DES is a novel stent system combining a biodegradable PLA and the new anti-restenoic drug biolimus. Biolimus is a semi-synthetic analog of sirolimus wherein the hydroxyl moiety at position 42 is modified to an ethoxyethyl ether group. As with rapamycin, the mechanism of action of biolimus consists of forming a complex with intracellular 12-kDa FK506-binding protein (FKBP-12), which binds to the mammalian target of rapamycin (mTOR) and reversibly inhibits cell-cycle transition of proliferating smooth muscle cells.The antiproliferative potency of biolimus is similar to that of sirolimus; however, it is approximately 10-fold more lipophilic than sirolimus, which results in rapid absorption of the drug into fatty tissues and reduced systemic exposure. The Biomatrixs DES is produced by the absorption of a 1:1 combination of biolimus and PLA on a flexible stainless steel stent. The precision automated coating method used in the production of the stent ensures the PLA biolimus combination is applied solely to the abluminal surface of the stent. PLA is co-released with biolimus over 6 9 months, and biodegraded initially to lactic acid, and eventually to carbon dioxide and water.

Originator

Biosensors (United States)

Uses

Umirolimus is a semi-synthetic macrocyclic lactone prepared from rapamycin by selective alkylation of the 42-hydroxy group, providing one of most hydrophobic tacrolimus analogues. Umirolimus has been targeted for use in stents and medical devices to suppress localised immunoreaction. Like all tacrolimus analogues, umirolimus binds to receptor protein, FKBP12. The complex then binds to mTOR and prevents it from interacting with target proteins. Umirolimus is extensively cited in the literature with over 70 citations.

Uses

Umirolimus is one of two promising agents for the treatment of peripheral artery disease (PAD) and minimize restenosis. Umirolimus is a medical device to suppress localised immunoreaction.

brand name

Biomatrix

Synthesis

The synthesis involves the preparation of the ethoxyethyl triflate 18 which was obtained by reacting ethoxyethanol 17 with triflic anhydride in dichloromethane in the presence of 2,6-lutidine at 0 ??C. Selective alkylation of rapamycin 19 alcohol at C-42 with crude triflate 18 in a mixture of toluene and 2,6-lutidine at 60 ??C gave biolimus A9 II in 25% isolated yield.

Synthesis_851536-75-9

UMiroliMus Preparation Products And Raw materials

Raw materials

Preparation Products

Global( 29)Suppliers
Supplier Tel Email Country ProdList Advantage
Hubei Jusheng Technology Co.,Ltd.
18871490254 linda@hubeijusheng.com CHINA 28180 58
TargetMol Chemicals Inc.
+1-781-999-5354 +1-00000000000 marketing@targetmol.com United States 19892 58
BOC Sciences
+16314854226 inquiry@bocsci.com United States 19743 58
Aladdin Scientific
+1-833-552-7181 sales@aladdinsci.com United States 52927 58
LGM Pharma 1-(800)-881-8210 inquiries@lgmpharma.com United States 2127 70
ChemStrong Scientific Co.,Ltd 0755-0755-66853366 13670046396 sales@chem-strong.com China 17994 56
Lynnchem 86-(0)29-85992781 17792393971 info@lynnchem.com China 4587 58
Novachemistry 44-20819178-90 02081917890 info@novachemistry.com United Kingdom 4381 58
Wuhan FengyaoTonghui Chemical Products Co., Ltd. 027-87466105 15377573527 2678564200@qq.com China 17997 58
Shanghai Hongye Biotechnology Co. Ltd 400-9205774 sales@glpbio.cn China 6870 58
BioliMus BioliMus, BioliMus A9, TRM 986 BIOLIMUS A9 UMiroliMus Rapamycin, 42-O-(2-ethoxyethyl)- BioliMus A9 UMiroliMus TRM 986 TRM986 TRM-986 851536-75-9 C55H87NO14 Immunosuppressant API